Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.0
6.0
Journals
Cells
Special Issues
Recent Advancements in the Regulated Cell Death
share announcement

Recent Advancements in the Regulated Cell Death

A special issue of Cells (ISSN 2073-4409).

Deadline for manuscript submissions: closed (30 January 2024) | Viewed by 2007

Special Issue Editors

Dr. Suchismita Raha

E-Mail Website
Guest Editor
1. Department of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Republic of Korea
2. Institute of Molecular Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA
Interests: tumor microenvironment; anti-cancer targets; cell signaling; cancer; programmed cell death; apoptosis; autophagy; lysosomal death; mitochondrial dysfunction; inflammatory disorder; protein-protein network; biomarker
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Gon Sup Kim

E-Mail Website
Guest Editor
Research Institute of Life Science, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Republic of Korea
Interests: bioactive therapeutics; monomer drug research; anti-cancer drug treatment; apoptosis; cell signaling pathways; anti-inflammatory disease drug treatment; protein biomarker
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

With the emerging technology, programmed cell death and its mechanism have progressed immensely, identifying new targets in biological development and therapeutics.

The types of programmed cell death or regulated cell death explored in the last decades are apoptosis, autophagy, necroptosis, necrosis, pyroptosis, paraptosis, ferroptosis, anoikis, NETosis, oxeiptosis, parthanatos etc. Recently, two unique forms of cell death named PANoptosis and cuproptosis, have been witnessed by researchers, which ensures all new modes of investigation in the field of regulated cell death that contribute to a wide range of understanding on the physiological and pathologicalmechanisms.

One of the crucial roles of regulated cell death is its interplay between the different cell death programs and the activation of proteases in their cleaved forms. It is very important to emphasize these potential modes of regulated cell death and understand their implications and regulations in various therapeutic strategies for treating diseases.

The field of programmed cell death is constantly evolving and expanding its gain of interest through scientific endeavours, providing insights into new areas of novel therapeutic targets in drug development and homeostasis.

This special issue of Cells welcomes submissions of original research articles and reviews covering recent advancements in regulated cell death and breakthroughs in therapy and development.

Dr. Suchismita Raha
Prof. Dr. Gon Sup Kim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • regulated cell death
  • advancements in programmed cell death
  • modes of cell death
  • cell death breakthroughs in novel therapeutic targets
  • new mechanism of cell death in homeostasis
  • programmed cell death interplay

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 4956 KiB  
Article
The Identification of a Novel Nucleomodulin MbovP467 of Mycoplasmopsis bovis and Its Potential Contribution in Pathogenesis
by Abdul Raheem, Doukun Lu, Abdul Karim Khalid, Gang Zhao, Yingjie Fu, Yingyu Chen, Xi Chen, Changmin Hu, Jianguo Chen, Huanchun Chen and Aizhen Guo
Cells 2024, 13(7), 604; https://doi.org/10.3390/cells13070604 - 29 Mar 2024
Viewed by 855
Abstract
Mycoplasmopsis bovis is a causative agent of crucial diseases in both dairy and beef cattle leading to substantial economic losses. However, limited control measures for M. bovis-related diseases exist due to a lack of understanding about the virulence factors of this pathogen, [...] Read more.
Mycoplasmopsis bovis is a causative agent of crucial diseases in both dairy and beef cattle leading to substantial economic losses. However, limited control measures for M. bovis-related diseases exist due to a lack of understanding about the virulence factors of this pathogen, a common challenge in mycoplasma research. Consequently, this study aimed to characterize a novel nucleomodulin as a virulence-related factor of M. bovis. Employing bioinformatic tools, we initially predicted MbovP467 to be a secreted protein with a nuclear localization signal based on SignalP scores and the cNLS (Nuclear Localization Signal) Mapper, respectively. Subsequently, the MbovP467 gene was synthesized and cloned into a pEGFP plasmid with EGFP labeling to obtain a recombinant plasmid (rpEGFP-MbovP467) and then was also cloned in pET-30a with a consideration for an Escherichia coli codon bias and expressed and purified for the production of polyclonal antibodies against the recombinant MbovP467 protein. Confocal microscopy and a Western blotting assay confirmed the nuclear location of MbovP467 in bovine macrophages (BoMacs). RNA-seq data revealed 220 up-regulated and 20 down-regulated genes in the rpEGFP-MbovP467-treated BoMac group compared to the control group (pEGFP). A GO- and KEGG-enrichment analysis identified associations with inflammatory responses, G protein-coupled receptor signaling pathways, nuclear receptor activity, sequence-specific DNA binding, the regulation of cell proliferation, IL-8, apoptotic processes, cell growth and death, the TNF signaling pathway, the NF-κB signaling pathway, pathways in cancer, and protein families of signaling and cellular processes among the differentially expressed up-regulated mRNAs. Further experiments, investigating cell viability and the inflammatory response, demonstrated that MbovP467 reduces BoMac cell viability and induces the mRNA expression of IL-1β, IL-6, IL-8, TNF-α, and apoptosis in BoMac cells. Further, MbovP467 increased the promoter activity of TNF-α. In conclusion, this study identified a new nucleomodulin, MbovP467, for M. bovis, which might have an important role in M. bovis pathogenesis. Full article
(This article belongs to the Special Issue Recent Advancements in the Regulated Cell Death)
►▼ Show Figures

Figure 1

20 pages, 7576 KiB  
Article
Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration
by Yujong Yi, Seon-Hong Pyun, Chae-Yeon Kim, Gyeongju Yun, Eunhwa Kang, Seoyoun Heo, Irfan Ullah and Sang-Kyung Lee
Cells 2024, 13(6), 548; https://doi.org/10.3390/cells13060548 - 20 Mar 2024
Viewed by 867
Abstract
Age-related macular degeneration (AMD), characterized by macular retinal degeneration, poses a significant health concern due to the lack of effective treatments for prevalent dry AMD. The progression of AMD is closely linked to reactive oxygen species and Fas signaling, emphasizing the need for [...] Read more.
Age-related macular degeneration (AMD), characterized by macular retinal degeneration, poses a significant health concern due to the lack of effective treatments for prevalent dry AMD. The progression of AMD is closely linked to reactive oxygen species and Fas signaling, emphasizing the need for targeted interventions. In this study, we utilized a NaIO3-induced retinal degeneration mouse model to assess the efficacy of Fas-blocking peptide (FBP). Intravitreal administration of FBP successfully suppressed Fas-mediated inflammation and apoptosis, effectively arresting AMD progression in mice. We developed a 6R-conjugated FBP (6R-FBP) for eye drop administration. 6R-FBP, administered as an eye drop, reached the retinal region, attenuating degeneration by modulating the expression of inflammatory cytokines and blocking Fas-mediated apoptosis in rodent and rabbit NaIO3-induced retinal degeneration models to address practical concerns. Intravitreal FBP and 6R-FBP eye drops effectively reduced retinal degeneration and improved retinal thickness in rodent and rabbit models. This study highlights the therapeutic potential of FBP, particularly 6R-FBP as an eye drop, in inhibiting Fas-mediated cell signaling and protecting against retinal cell death and inflammation in dry AMD. Future investigations should explore the translational prospects of this approach in primates with eye structures comparable to those of humans. Full article
(This article belongs to the Special Issue Recent Advancements in the Regulated Cell Death)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop